Barclays PLC Buys 71,730 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Barclays PLC lifted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 346.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 92,444 shares of the company's stock after acquiring an additional 71,730 shares during the quarter. Barclays PLC owned approximately 0.19% of Prestige Consumer Healthcare worth $6,665,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC lifted its holdings in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company's stock valued at $30,000 after purchasing an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock worth $35,000 after acquiring an additional 433 shares in the last quarter. nVerses Capital LLC boosted its position in Prestige Consumer Healthcare by 200.0% during the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company's stock worth $43,000 after acquiring an additional 400 shares during the period. Huntington National Bank grew its stake in Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after acquiring an additional 181 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Prestige Consumer Healthcare by 106.9% in the 2nd quarter. Blue Trust Inc. now owns 867 shares of the company's stock valued at $63,000 after purchasing an additional 448 shares during the period. Institutional investors and hedge funds own 99.95% of the company's stock.

Analyst Ratings Changes

PBH has been the subject of several research reports. DA Davidson restated a "buy" rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Jefferies Financial Group restated a "hold" rating and set a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Sidoti downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target on the stock. in a research note on Monday, December 9th. Finally, StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $85.25.

Prestige Consumer Healthcare Stock Down 0.2 %

PBH stock traded down $0.13 during trading hours on Thursday, hitting $78.66. The company's stock had a trading volume of 206,525 shares, compared to its average volume of 252,444. The company has a market capitalization of $3.89 billion, a PE ratio of 19.14, a price-to-earnings-growth ratio of 2.32 and a beta of 0.49. The stock has a 50 day moving average price of $78.86 and a two-hundred day moving average price of $72.90. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a 12 month low of $57.95 and a 12 month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. During the same period in the prior year, the business posted $1.07 earnings per share. The business's quarterly revenue was down .9% on a year-over-year basis. On average, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current year.

Insider Activity at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the firm's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Mary Beth Fritz sold 9,885 shares of the business's stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the transaction, the senior vice president now directly owns 18,835 shares of the company's stock, valued at approximately $1,543,904.95. This represents a 34.42 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.